BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37946161)

  • 1. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.
    Wang P; Xia L
    BMC Cancer; 2023 Nov; 23(1):1083. PubMed ID: 37946161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
    Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
    Xu Y; Wang Y; Gong J; Zhang X; Peng Z; Sheng X; Mao C; Fan Q; Bai Y; Ba Y; Jiang D; Yang F; Qi C; Li J; Wang X; Zhou J; Lu M; Cao Y; Yuan J; Liu D; Wang Z; Fang J; Shen L
    Gastric Cancer; 2021 Jul; 24(4):913-925. PubMed ID: 33945049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
    Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
    EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
    Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
    Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
    Peng Z; Liu T; Wei J; Wang A; He Y; Yang L; Zhang X; Fan N; Luo S; Li Z; Gu K; Lu J; Xu J; Fan Q; Xu R; Zhang L; Li E; Sun Y; Yu G; Bai C; Liu Y; Zeng J; Ying J; Liang X; Xu N; Gao C; Shu Y; Ma D; Dai G; Li S; Deng T; Cui Y; Fang J; Ba Y; Shen L
    Cancer Commun (Lond); 2021 Nov; 41(11):1173-1182. PubMed ID: 34665942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
    Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
    BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
    Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China.
    Chen J; Wang M; Qi X; Long H; Qi N; Wu L; Ke M; Shao S; Li P; Chen Y; Wang W; Zhu S; Qi X; Li G
    Clin Genitourin Cancer; 2024 Jun; 22(3):102093. PubMed ID: 38762350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
    Sheng X; Wang L; He Z; Shi Y; Luo H; Han W; Yao X; Shi B; Liu J; Hu C; Liu Z; Guo H; Yu G; Ji Z; Ying J; Ling Y; Yu S; Hu Y; Guo J; Fang J; Zhou A; Guo J
    J Clin Oncol; 2024 Apr; 42(12):1391-1402. PubMed ID: 37988648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
    J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Wen F; Lin T; Zhang P; Shen Y
    Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
    Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
    Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
    Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
    Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
    Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
    [No Abstract]   [Full Text] [Related]  

  • 16. A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
    Hong X; Chen X; Wang H; Xu Q; Xiao K; Zhang Y; Chi Z; Liu Y; Liu G; Li H; Fang J; Lin T; Zhang Y
    Adv Sci (Weinh); 2023 Nov; 10(32):e2302377. PubMed ID: 37824205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression.
    Chen Z; Yuan J; Xu Y; Zhang C; Li Z; Gong J; Li Y; Shen L; Gao J
    Front Pharmacol; 2021; 12():757994. PubMed ID: 35069192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
    Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
    Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma.
    Qu W; Fu C; Han W; Luo H; Quan J; Chen L; Liao Y; Hu C; Hu H; Niu Y; Xu D; Chen M; Chen J; Liu Y; Chen G; Luo Z; Shi B; Sun Y; Zhou F; Zhou A
    Eur J Cancer; 2024 Jul; 205():114096. PubMed ID: 38772302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.